Psoriatic Arthritis

Subjects reported pain at the injection site was significantly reduced with the One-Press autoinjector pen and 98% chose the pen as their preferred medication delivery system.

The repository corticotropin injection is designed to help patients manage their medication alongside a range of chronic and acute autoimmune and inflammatory conditions.

Responders at week 104 demonstrated more significant changes from baseline and achieved normative values in PROs compared with non-responders.

Test your knowledge of juvenile idiopathic arthritis (JIA) treatment recommendations from the 2021 ACR guideline on JIA with this quiz.

PASI100 was achieved by 41.7% of patients at week 16 and 70.6% at week 260.

Most men (91.7%) and women (72.7%) with psoriatic arthritis exhibited sexual dysfunction.

Independent predictors of physical activity avoidance were anxiety symptoms—as determined by HADS—and the SF-36 Physical Component Score.

Test your knowledge of systemic juvenile idiopathic arthritis (JIA) treatment recommendations from the 2021 ACR guideline on JIA with this quiz.

At the end of the intervention period, all patients displayed a significant reduction in weight of approximately 3 BMI points.

Test your knowledge of active temporomandibular joint (TMJ) arthritis treatment recommendations from the 2021 ACR guideline on JIA with this quiz.

Older age and a greater BMI are associated with having a shorter interval between psoriasis and PsA diagnoses, a study found.

Patients with PsA who achieved low disease activity had a 76% - 79% improvement in the Global Assessment and Pain composite.

A study found patients with PsA have greater healthcare costs for herpes zoster than patients without PsA.

Administrative claims database analysis revealed a lower AMD incidence in patients treated with JAK inhibitor therapy versus non–JAK-based immunotherapy.

Casey Schlacher discusses the FDA approval of the new weight-based oral solution, RINVOQ LQ (upadacitinib), for treating pediatric patients with arthritis, highlighting its importance for improving patient outcomes and quality of life.

Test your knowledge of active oligoarthritis treatment recommendations from the 2021 ACR guideline on JIA with this quiz.

An observational study found patients with chronic inflammatory diseases who smoke may respond less to biologics than non-smokers.

Gerd Burmester, MD, discusses the favorable long-term safety data of upadacitinib treatment across rheumatic diseases.

A survey shows females with PsA have a greater disease burden than males with PsA.

If approved, zasocitinib could become a leading oral treatment for PsA.

A study found patients with psoriasis and psoriatic arthritis had a polyneuropathy relative risk of 22.09. However, an analysis revealed the neuropathy risk was not significant.

Older children (aged >5 years) with JIA exhibited a 40% to 45% higher point prevalence of active disease at month 12 when compared with younger patients.

Discontinuation was less likely in the prospective Patient Support Program (PSP) group compared with the retrospective non-PSP group.

A study describes the structure and function differences of the Achilles tendon for PsA patients who self-report pain and those who don’t.

Data showed a significant reduction in pain for patients with psoriatic arthritis and inadequate response to TNF treated with guselkumab compared with placebo.

Treatment with guselkumab led to rapid, clinically meaningful improvements in disease activity among patients with severe psoriatic arthritis, which were maintained through 2 years.

Results revealed cDAPSA can help providers accurately measure the level of disease activity in patients and predict whether the patient will have radiographic progression.

Patients with psoriasis on biological agents might have a lower PsA risk than those on methotrexate, but patients on topical therapy have an even lower risk, a study found.

Among patients with PsA, men tend to present more peripheral joint movement, and women tend to exhibit more axial involvement, a new study found.

Adults with active PsA treated with guselkumab exhibited durable achievement of study endpoints associated with disease control, irrespective of baseline characteristics.